Tianeptine does not show up on standard drug tests. The routine urine drug screens used by employers, probation officers, and emergency rooms are designed to catch a specific set of common substances, and tianeptine is not among them. Even though tianeptine acts on opioid receptors in the brain, its chemical structure is different enough from drugs like morphine, oxycodone, and fentanyl that the antibody-based tests used in standard panels simply do not recognize it. Detecting tianeptine requires a specialized laboratory method that most facilities do not run unless they are specifically looking for it.
Why Standard Panels Miss It
Most workplace, clinical, and legal drug tests rely on immunoassay technology. These tests use antibodies engineered to bind to a particular drug or its metabolites. A standard five-panel or ten-panel screen typically covers amphetamines, cannabinoids, cocaine, opiates, phencyclidine (PCP), benzodiazepines, barbiturates, and sometimes methadone or oxycodone. The opiate portion of these panels is calibrated to detect morphine-like compounds, and expanded opiate panels pick up semi-synthetics like oxycodone and hydrocodone. Tianeptine, however, is structurally classified as an atypical tricyclic antidepressant, not as a classical opioid.
Here is where things get counterintuitive. Tianeptine has been shown to be a moderately potent agonist at the mu opioid receptor, the same receptor targeted by heroin and prescription painkillers, and it also has some activity at the delta opioid receptor.1ACS Chemical Neuroscience. Medicinal Chemistry and Pharmacology of Tianeptine But “acts on opioid receptors” and “looks like an opioid to an antibody test” are completely different things. The immunoassay antibodies are matching molecular shape, not pharmacological effect. Tianeptine’s three-ring tricyclic backbone with a chlorinated side chain and aminoheptanoic acid tail looks nothing like the phenanthrene core of morphine or the piperidine ring of fentanyl. The antibodies on a standard opiate panel have no reason to bind to it.
In one documented case of acute toxicity from intravenous tianeptine use, the patient’s urine screened negative for common drugs of abuse and also negative for total tricyclic antidepressants.2PubMed Central. Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine That second detail is worth pausing on. Tianeptine is technically classified as a tricyclic antidepressant, yet it does not trigger the TCA immunoassay either. The TCA screens are designed around the older, more common tricyclics like amitriptyline and imipramine, and tianeptine’s structure is atypical enough to fly under that radar too.
The Only Way to Detect Tianeptine Reliably
If a clinician or forensic investigator specifically suspects tianeptine involvement, the tool of choice is liquid chromatography-tandem mass spectrometry, usually abbreviated LC-MS/MS. This method separates and identifies compounds based on their exact molecular weight and fragmentation pattern, so it can distinguish tianeptine from every other substance in a sample with high specificity. A forensic toxicology laboratory in Texas developed and validated just such a method after encountering the first known tianeptine fatalities in the United States, where postmortem blood concentrations were measured at 2.0 mg/L and 8.4 mg/L.3Journal of Analytical Toxicology. Case Reports of Fatalities Involving Tianeptine in the United States
The problem is that LC-MS/MS is not a routine screening tool. It requires expensive equipment, trained technicians, and a deliberate decision to include tianeptine on the analyte list. Hospitals running a quick tox screen in the emergency department are not going to catch it. Workplace drug testing labs are not going to catch it. Even forensic labs may not catch it unless they have been alerted that tianeptine is a possibility. A systematic review examining tianeptine’s growing public health impact noted explicitly that standard urine drug screens do not detect it, and recommended that clinicians be trained to request expanded toxicology panels when tianeptine use is suspected.4PubMed Central. Gas station heroin- tianeptine and its impact: a systematic review and exploratory analysis
Can Tianeptine Cause a False Positive for Anything Else?
Based on the available evidence, tianeptine does not appear to trigger false positives for opioids, tricyclic antidepressants, or other drug classes on standard immunoassay panels. The case report of intravenous tianeptine toxicity mentioned earlier is a useful illustration: despite very high drug levels in the patient’s system, the urine screen came back clean across the board.5PubMed Central. Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine This is consistent with what you would expect given the structural mismatch between tianeptine and the target compounds in standard panels.
That said, false positives on immunoassay drug tests are a well-known phenomenon caused by all sorts of substances, from over-the-counter cold medications to certain antibiotics. The specifics depend on the exact assay kit, the manufacturer, and the cutoff levels used by the lab. If you are taking tianeptine and test positive for something unexpected, the appropriate next step is always a confirmatory test using mass spectrometry, which will definitively sort out what is actually present in your sample.
Why This Matters More Than It Used To
Tianeptine is approved as a prescription antidepressant for major depressive disorder in several countries in Europe, Asia, and Latin America, but it has never been approved by the FDA in the United States.6PubMed Central. Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review Despite that, tianeptine has been widely available in the U.S. as a dietary supplement or research chemical, often sold under brand names like ZaZa and Tianna at gas stations and convenience stores. The nickname “gas station heroin” reflects both where it is sold and why people seek it out: at high enough doses, tianeptine produces opioid-like euphoria, and people using it recreationally can develop dependence and withdrawal symptoms that closely resemble opioid withdrawal.
The fact that tianeptine evades standard drug tests has real consequences in this context. A person experiencing opioid-like withdrawal symptoms may present to an emergency department, get a clean tox screen, and leave clinicians confused about the diagnosis. An individual on probation or in a drug court program may be using tianeptine heavily while passing every mandated drug test. Employers screening for substance use will not catch it. The gap between tianeptine’s pharmacological reality and the testing infrastructure designed to identify drug use creates a blind spot that clinicians and others are only beginning to address.
What People Use Tianeptine With
Tianeptine rarely exists in isolation when it shows up in problematic use. An analysis of social media descriptions of tianeptine use found that it was frequently associated with other substances, particularly kratom, phenibut, and racetams.7PubMed Central. When an obscurity becomes a trend: Social-media descriptions of tianeptine use and associated atypical drug use This pattern matters for drug testing because kratom and phenibut also evade standard panels. A person co-using these substances could be pharmacologically impaired, experiencing withdrawal, or at risk for overdose while producing a completely clean drug screen.
This cocktail of “novel” or “atypical” substances represents a broader challenge for drug testing as it currently works. The panels were designed in an era when the drugs of concern were a relatively short list of well-characterized compounds. The proliferation of substances that act on opioid, GABAergic, and other receptors but do not structurally resemble the classic drugs those panels are built to catch means the gap between what drug tests can find and what people are actually taking continues to widen.
What Happens in Forensic Settings
When tianeptine involvement is suspected in a death or serious poisoning, forensic toxicology labs can detect and quantify it, but only if they know to look. In one early European case report of a fatal tianeptine intoxication, postmortem analysis found tianeptine concentrations of 5.1 micrograms per milliliter in blood and 2.0 micrograms per milliliter in urine, along with high concentrations in the liver and stomach contents.8PubMed. Fatal intoxication with tianeptine (Stablon) The U.S. fatalities documented in Texas similarly required development of a purpose-built LC-MS/MS method after the first case prompted investigation.9Journal of Analytical Toxicology. Case Reports of Fatalities Involving Tianeptine in the United States
The practical takeaway is that tianeptine can be found if people are specifically searching for it. The limitation is awareness, not technology. As tianeptine-related harms have increased, more forensic labs have added it to their analytical menus, but coverage is uneven. A lab in a state that has recently scheduled tianeptine or experienced related fatalities is more likely to include it than one that hasn’t.
Practical Scenarios for Different Readers
The answer to “does tianeptine show up on a drug test” depends on what kind of test you are facing and who ordered it. Here is how the major scenarios break down:
- Workplace drug test: Almost certainly no. These are standard immunoassay panels, and tianeptine will not trigger a positive for any of the tested drug classes.
- Probation or drug court: Also unlikely on standard panels. However, some jurisdictions are beginning to use expanded testing as awareness of tianeptine grows. If your supervising officer or court has specifically added tianeptine to the panel, it could be detected.
- Emergency department: A standard tox screen will miss it. If you are seeking medical care and tianeptine is involved, tell your providers directly rather than relying on the drug screen to reveal it. This is especially important if you are experiencing withdrawal or overdose symptoms.
- Insurance or military testing: Military drug testing programs occasionally update their panels, and some insurance screening programs use broader analytical methods. Whether tianeptine is included varies by program and is not publicly standardized.
- Forensic or death investigation: Forensic labs can detect tianeptine with targeted analysis, but it is not part of routine postmortem screening everywhere.
Tianeptine’s Metabolites and How Long They Stick Around
Tianeptine is metabolized in the body into several compounds, the most notable being a metabolite called MC5. In healthy individuals, tianeptine itself has a short half-life of roughly two to three hours, meaning it clears the blood relatively quickly. MC5 hangs around somewhat longer. A study of tianeptine disposition in patients with chronic kidney disease found that while renal failure did not significantly change how the parent drug behaved, the MC5 metabolite’s half-life roughly tripled in those patients compared to healthy controls.10PubMed. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis
For anyone wondering how long tianeptine could theoretically be detectable in urine or blood, the short half-life of the parent compound means it washes out relatively fast in people with normal kidney function. But “fast” in pharmacological terms and “invisible to a drug test” are different questions. Even if tianeptine and MC5 are present in urine at the time of collection, a standard immunoassay panel will not detect them. You would need a targeted LC-MS/MS assay, and even then, the detection window is narrower than for most drugs of abuse because of that short half-life. In forensic cases involving fatal overdoses, detection was possible because concentrations were extremely high, often many times what would be seen with therapeutic use.
The Changing Regulatory Landscape
Several U.S. states have moved to schedule or ban tianeptine in recent years, and the FDA has issued warnings about products containing it. As of the mid-2020s, states including Alabama, Michigan, Indiana, and others have classified tianeptine as a controlled substance. These regulatory actions may eventually push testing labs to add tianeptine to their panels, particularly in states where it is now illegal. When a substance becomes a scheduled drug, the legal system’s interest in detecting it increases, and testing protocols tend to follow.
At the federal level, tianeptine remains unscheduled, though the DEA has expressed concern. If federal scheduling occurs, the ripple effects on drug testing would be significant: federal workplace testing programs, military panels, and the standard SAMHSA guidelines that shape much of the testing industry could all be updated to include it. Until that happens, tianeptine occupies an unusual regulatory gray zone where it can cause clinically significant opioid-like effects, withdrawal, and even death, while remaining invisible to the drug testing infrastructure that exists to catch exactly those kinds of substances.
When Someone Else’s Tianeptine Use Affects You
If you are a clinician, the practical lesson is that a clean drug screen does not rule out opioid-receptor-mediated toxicity. A patient presenting with pinpoint pupils, respiratory depression, and altered consciousness who screens negative for opioids may have taken tianeptine, kratom, or another substance outside the standard panel. Naloxone (the opioid reversal agent) has been reported to reverse tianeptine’s effects in some clinical scenarios, which makes sense given the mu opioid receptor mechanism, but the evidence base for this is still thin and mostly consists of case reports and clinical observations.
If you are a family member or friend worried about someone’s substance use, a negative drug test may provide false reassurance. The person may genuinely not be using any of the substances the test screens for and still be pharmacologically dependent on something that the test was never designed to find. If you suspect tianeptine specifically, communicating that concern to a healthcare provider is more useful than relying on test results. Awareness that this blind spot exists is, for now, the most effective tool available.